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Iron Burden Before BMT (Mean 	 SEM)
Disease N
Serum
Iron
(g/dl)
Ferritin
(ng/ml)
TIBC
(g/dl)
ALT
(U/L)
RBC
(ml/kg)
LIC (mg
Fe/gm liver
dry wt)
TM 6 165  301 1964.3  180 214  16.8 141.7  67.1 561.7  277.4 15.1  1.4
SCD 4 146.5  46.3 2124.5  1053 233  36.3 67.3  39.4 200.8  106.9 14.7  7.3
AML 5 96  0 2229.5  785.5 241  59 31  1.6 311.1  114.8 ND
TM, Thalassemia major; SCD, Sickle cell disease; AML, acute
myelogenous leukemia; TIBC, total iron binding capacity;
ALT, alanine transaminase; RBC, volume RBC transfused;
LIC, Liver iron concentration.
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DESCRIPTIVE ANALYSIS OF CHANGING TOXICITY PROFILES FOR 30
AND 100 DAY MORTALITY AFTER MATCHED RELATED DONOR (MRD)
ALLOGENEIC (ALLO) HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) USING PO VS IV BUSULFAN (BU) BASED CONDITIONING REG-
IMENS
Gupta, S.; Cole, S.W.; Salzman, D.E.; Ashraf, K.; Aggarwal, C.;
Vaughan, W.P. Bone Marrow Transplantation Program, University of
Alabama at Birmingham, Birmingham, AL.
We have been using BU based preparative regimens in ALLO
MRD HSCT for hematological malignancies since 3/92. Prior to
3/99, 135 pts were treated with po BU in BU/Cy2, BU/Cy/VP16,
and BU/Fludara preparative regimens (po group). Between 3/99
and 5/04, 97 pts received iv BU with pharmacokinetic (PK) guided
dosing in one of the same three regimens (iv group). The distri-
bution of diagnoses was similar in the two groups. In the po group
the diagnoses were acute Leukemia (47), NHL (38), CML (37),
HD (10) and other (3). In the iv group the diagnoses were acute
Leukemia (34), NHL (32), CML (20) HD (3) and other (8). The
female/male ratio was also similar in the two groups (po 63/72, iv
44/53). The pts in the iv group were older (45 yrs) (63/97 vs
57/135, p0.0006, 2), had a slightly higher ASBMT relapse risk
score (72% vs 66%, I/HR), a higher ratio of ASBMT HR CML pt
(11/20 vs 12/37) and more pts with less than 10/10 match (8% vs
3%). Despite the higher risk for both relapse and transplant related
mortality in the iv group, the 30 and 100 d mortality was similar for
the two groups (4% and 31% for iv BU: 8% and 28% for po BU).
Deﬁning cause of death as the initiating event or ﬁrst organ failure
that led to death, we found that, not unexpectedly, death due to
Hepatic Veno-Occlusive Disease (HVOD) was eliminated with the
use of PK directed iv BU (0/21 vs 8/34, p0.014, 2). GVHD/
immunodeﬁciency and cardio-pulmonary toxicity were not in-
creased in the higher risk iv group, but these two causes remained
signiﬁcant and together accounted for 67% of the overall non
relapse mortality in the combined population. However, death due
to progression of primary disease was greater in the iv group (9/30
vs 4/38, p0.04, 2) reﬂecting their greater ASBMT relapse risk.
Because of elimination of HVOD and no increase in any other
cause of non-relapse mortality as a result of pharmacokinetic
guided iv BU targeting, we are now able to transplant higher risk
pts without an increase in the 30 or 100 d mortality. These results
are a part of incremental multiple center pharmaceutical and sup-
portive care efforts directed towards increasing the value of my-
eloablative transplants to older and higher risk pt (Table 1).
Cause of Death—100 d Mortality by Route of BU Administration
Progressive
Disease
Veno-
Occlusive
Disease
GVHD/
Immunodeficiency
Cardio-
Pulmonary Others
po 4 8 15 7 4
iv 9 0 7 8 6
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THE REQUIREMENT OF MHC CLASS II FOR DONOR CD4CD25 T
CELL-MEDIATED SUPPORT OF EARLY ALLOGENEIC PROGENITOR CELL
ENGRAFTMENT
Hanash, A.M.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
CD4CD25 regulatory T cells have recently emerged as a
potential modality for suppression of GVHD and promotion of
allogeneic engraftment. In a fully allogeneic MHC mismatched
model utilizing C57BL/6 (B6) T cell-depleted bone marrow (BM-
TCD) and sublethally conditioned (7.0 Gy TBI) BALB/c recipi-
ents, we have demonstrated that donor CD4CD25 T cells are
capable of supporting multi-potential and lineage-committed do-
nor progenitor activity as well as long-term chimerism and toler-
ance. In order to pursue the potential for clinical application, we
sought to determine molecular and antigenic requirements in-
volved in the initial promotion of allogeneic engraftment. Al-
though an essential role for IL-10 has been demonstrated in certain
regulatory T cell models, augmentation of donor progenitors seven
days post-BMT did not require CD4CD25 T cell IL-10: co-
transplantation of 1  106 B6-wt or B6-IL-10/ CD4CD25 T
cells both signiﬁcantly increased GFP splenic CFU-GM when
transplanted with 2  106 B6-GFP BM-TCD into BALB/c recip-
ients (mean CFU 	 SE: BM alone, 657.5 	 248.2; BM  wt,
1972 	 331.5; BM  IL-10/, 1965 	 401.7; both p
.05 vs. BM
alone). Assessment of the antigenic requirements for activation of
progenitor support demonstrated that donor CD4CD25 T cells
did not require alloreactivity to support progenitors, as BALB/c 
B6 F1 CD4CD25 T cells signiﬁcantly increased B6 CFU-GM
in BALB/c recipients (p
.001 vs. BM alone). However, B6
CD4CD25 T cells failed to augment MHC-disparate C3H/HeJ
CFU-GM in BALB/c recipients (p.05 vs. BM alone), suggesting
that donor CD4CD25 T cells might require recognition of
syngeneic MHC for progenitor support. Indeed, augmentation of
donor CFU-GM was abrogated when B6 CD4CD25 T cells
were co-transplanted with B6-MHC class II/ marrow into
BALB/c recipients (p.05 vs. BM alone). In conclusion, donor
CD4CD25 T cells capable of promoting long-term engraft-
ment and tolerance do not require IL-10 for support of initial
donor progenitor activity, however progenitor support does re-
quire co-transplantation with syngeneic MHC class II-expressing
marrow. Strikingly, there may be distinct antigenic requirements
for promotion of engraftment and suppression of GVHD, suggest-
ing that the CD4CD25 T cells responsible for these effects may
be distinct as well. Further determination of the role of donor
MHC class II may prove essential for proper construction of
CD4CD25 T cell-based allo-engraftment protocols.
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ABSENCE OF CD80/86 EXPRESSION ON DONOR BONE MARROW IS
SUFFICIENT TO CIRCUMVENT T CELL MEDIATED RESISTANCE FOL-
LOWING EXPERIMENTAL “MINI” MHC-MATCHED ALLOGENEIC BMT
Zimmerman, Z.F.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
Successful MHC-matched allogeneic BMT following non-my-
eloablative conditioning requires overcoming immune mediated
resistance by alloreactive host T cells to achieve engraftment.
Manipulation of donor APC’s may be a clinically feasible strategy
to achieve this aim. In the current study, donor BM from CD80/
86/ mice was transplanted to determine the requirements of
donor APC in eliciting resistance in pre-clinical “mini” (5.5 Gy
TBI) BMT models. Non donor antigen sensitized (“naı¨ve”) and
donor antigen sensitized (“memory”) recipients were transplanted.
“Naı¨ve” C3H.SW (H-2b) mice were transplanted with 4  106
TCD-BMC from B6-wt or CD80/86/ donors. All mice receiv-
ing B6-wt BM displayed brief donor cell presence peaking at day
7–10 post-BMT followed by disappearance (i.e. rejection) 4–5
weeks later. In contrast, C3H.SW mice receiving CD80/86/
marrow achieved and maintained signiﬁcant donor chimerism
(50%) in both B cell and importantly, T cell compartments.
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